<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815551</url>
  </required_header>
  <id_info>
    <org_study_id>AV-380-20-101</org_study_id>
    <nct_id>NCT04815551</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of AV-380 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, First-in-human, Randomized, Placebo Controlled, Double Blind, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AV-380 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to&#xD;
      evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in&#xD;
      healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal&#xD;
      antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15),&#xD;
      a cytokine involved in cancer-induced cachexia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (AEs) and treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Through study completion, an average of 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site safety and tolerability assessment</measure>
    <time_frame>Visit Day 1</time_frame>
    <description>Site injection tolerability will be assessed by the Investigator using a 4-level score (none, mild, moderate, severe) after IV infusion and SC injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hematology - hemoglobin</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Hemoglobin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hematology - hematocrit</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Hematocrit (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hematology - erythrocytes</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Erythrocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hematology - white blood cell count</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>White blood cell count with differential (neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelets) (X10(3)/UL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - sodium</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Sodium (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - potassium</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Potassium (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - calcium</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Calcium (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - chloride</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Chloride (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - CO2</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>CO2 (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - blood urea nitrogen</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Blood urea nitrogen (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - creatinine</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>creatinine (mg/dL), glucose, total proteins, triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - glucose</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Glucose (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - total proteins</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Total proteins (g/dL), triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - triglycerides</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Triglycerides (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - total cholesterol</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Total cholesterol (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - AST</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>AST (U/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - ALT</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>ALT (U/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - Gamma-glutamyltransferase</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Gamma-glutamyltransferase (U/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - Creatinine phosphokinase</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Creatinine phosphokinase (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - albumin</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Albumin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - alkaline phosphatase</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Alkaline phosphatase (U/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Blood chemistry - total bilirubin</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Total bilirubin (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Coagulation - partial thromboplastin time</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Activated partial thromboplastin time (secs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Coagulation - prothrombin time</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Prothrombin time (sec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Coagulation - International normalized ratio</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>International normalized ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hormonology</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Measured parameters: Hormonology (TSH, FSH (for post-menopausal women); Î²-HCG (for women of childbearing potential))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hormonology - TSH</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>TSH (mIU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Hormonology - FSH</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>FSH (mIU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - pH</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - protein</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Protein (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - glucose</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Glucose (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - leukocytes</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Leukocytes (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - nitrites</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Nitrites (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - ketones</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Ketones (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory measurements - Urinalysis - blood</measure>
    <time_frame>Visits Day 1 through Day 60</time_frame>
    <description>Blood (negative/positive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs measurements - Blood pressure</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Supine and standing systolic and diastolic blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs measurements - Heart rate</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Heart rate (beats/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs measurements - Body temperature</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Body temperature (degrees Celsius)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs measurements - Respiratory rate</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Respiratory rate (breaths/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) measurements - Mean heart rate</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>ECG mean heart rate (beats/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) measurements - PR interval</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>PR interval, aggregate (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) measurements - QRS axis</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>QRS axis (deg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) measurements - QTcF interval</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>QTcF interval, aggregate (msec)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection</measure>
    <time_frame>Visits Day 1 through D90</time_frame>
    <description>Cmax (maximum observed serum concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Tmax (time to reach maximum serum concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the serum level of GDF-15 with the dose and serum level of AV-380</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>Emax (maximum effect observed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the serum level of GDF-15 with the dose and serum level of AV-380</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>AUEC (area under the effect-time curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the serum level of GDF-15 with the dose and serum level of AV-380</measure>
    <time_frame>Visits Day 1 through Day 90</time_frame>
    <description>TEmax (time to reach maximum effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AV-380 immunogenicity in healthy subjects - anti-AV-380 antibodies (human anti-human antibodies [HAHA]) levels in serum.</measure>
    <time_frame>Visits Day 1 through Day 180</time_frame>
    <description>HAHA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AV-380 immunogenicity in healthy subjects - Monocyte chemoattractant protein 1 (MCP-1) levels in serum.</measure>
    <time_frame>Visits Day 1 and Day 2</time_frame>
    <description>Serum MCP-1 levels will be measured.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Cachexia</condition>
  <arm_group>
    <arm_group_label>AV-380 IV 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of AV-380 at dose level 4 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 IV 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of AV-380 at dose level 8 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 IV 13 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of AV-380 at dose level 13 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 IV 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of AV-380 at dose level 20 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 SC 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of AV-380 at dose level 4 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 SC 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of AV-380 at dose level 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV-380 SC 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of AV-380 at dose level 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-380</intervention_name>
    <description>AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.</description>
    <arm_group_label>AV-380 IV 13 mg/kg</arm_group_label>
    <arm_group_label>AV-380 IV 20 mg/kg</arm_group_label>
    <arm_group_label>AV-380 IV 4 mg/kg</arm_group_label>
    <arm_group_label>AV-380 IV 8 mg/kg</arm_group_label>
    <arm_group_label>AV-380 SC 1 mg/kg</arm_group_label>
    <arm_group_label>AV-380 SC 2 mg/kg</arm_group_label>
    <arm_group_label>AV-380 SC 4 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is sterile liquid for IV infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female volunteers, 18 to 50 years of age, inclusive.&#xD;
&#xD;
          2. A body mass index (BMI) between 18 and 30 kg/m2 and weight between 60 and 90 kg.&#xD;
&#xD;
          3. Healthy as indicated by a comprehensive clinical assessment (detailed medical history&#xD;
             and complete physical examination). Supine blood pressure (BP), heart rate (HR),&#xD;
             electrocardiogram (ECG) intervals and routine laboratory tests within the normal range&#xD;
             of the study center (see Appendix 4) or considered not clinically significant by the&#xD;
             Investigator. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and&#xD;
             total bilirubin must be &lt; 1.5 times the upper limit of the normal range (ULN). Total&#xD;
             bilirubin, if above 1.5 x ULN, is only acceptable with a history of Gilbert's&#xD;
             Syndrome.&#xD;
&#xD;
          4. Non-smoker or ex-smoker for longer than 6 months.&#xD;
&#xD;
          5. Sexually active pre-menopausal female subjects and female partners of male subjects&#xD;
             must use adequate contraceptive measures, while on study and for at least 100 days&#xD;
             after the IMP administration. Sexually active male subjects must use adequate&#xD;
             contraceptive measures, while on study and for at least 160 days after the last dose&#xD;
             of IMP. All fertile male and female subjects and their partners must agree to use a&#xD;
             highly effective method of contraception. Effective birth control includes hormonal&#xD;
             contraception (oral, intravaginal, transdermal, injectable or implantable),&#xD;
             intrauterine device (IUD) plus one barrier method; or 2 barrier methods. Effective&#xD;
             barrier methods are male or female condoms, diaphragms, and spermicides (creams or&#xD;
             gels that contain a chemical to kill sperm). Vasectomy (at least 3 months before IMP&#xD;
             administration) and vasectomized partner (provided that the partner is the sole sexual&#xD;
             partner of the trial participant and that the absence of sperm in the ejaculate has&#xD;
             been confirmed) are acceptable methods of contraception, as well as post-menopausal&#xD;
             female for at least 1 year (confirmed with serum follicle stimulating hormone [FSH] &gt;&#xD;
             25.8 IU/L at screening), or surgically sterilized female subjects. Abstinence is not&#xD;
             an acceptable contraception method. Female subjects who are of non-childbearing&#xD;
             potential due to a surgical procedure or medical condition must provide documentation,&#xD;
             and vasectomized male subjects must bring in the surgical report of the procedure.&#xD;
&#xD;
          6. Able to sign and understand an ICF and able to comply with study restrictions prior to&#xD;
             selection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence or history of any disorder that may prevent the successful completion of the&#xD;
             study.&#xD;
&#xD;
          2. Clinically significant abnormalities in laboratory test results (including hepatic and&#xD;
             renal panels, complete blood count, chemistry panel and urinalysis), such as:&#xD;
&#xD;
               -  White blood cell count &lt; 3.0x109/L.&#xD;
&#xD;
               -  Neutrophils &lt; 1.5x109/L or clinically abnormal according to the subject's ethnic&#xD;
                  group (must be &gt; 1.0x109/L for subjects of African descent).&#xD;
&#xD;
               -  Hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
               -  Platelet count &lt; 125x109/L or &gt; 450x109/L.&#xD;
&#xD;
               -  ALT &gt; 1.5 ULN.&#xD;
&#xD;
               -  AST &gt; 1.5 ULN.&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 ULN (except in the presence of Gilbert's syndrome).&#xD;
&#xD;
               -  Creatinine &gt; 1.2 ULN.&#xD;
&#xD;
               -  Sodium &lt; 132 mmol/L or &gt; 147 mmol/L.&#xD;
&#xD;
               -  Potassium &lt; 3.2 mmol/L or &gt; 5.5 mmol/L.&#xD;
&#xD;
               -  Chloride &lt; 93 mmol/L or &gt; 111 mmol/L.&#xD;
&#xD;
               -  Calcium &lt; 8.3 mmol/L or &gt; 10.7 mmol/L. Clinically significant abnormal values for&#xD;
                  all other laboratory parameters are at the investigator's discretion.&#xD;
&#xD;
          3. Any surgical or medical condition that may interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the investigational medicine product.&#xD;
&#xD;
          4. Any history of drug related hypersensitivity reaction.&#xD;
&#xD;
          5. Prior treatment with a monoclonal antibody.&#xD;
&#xD;
          6. Intercurrent illness as evidenced by, e.g., nausea, vomiting, fever, or diarrhea)&#xD;
             within 7 days before D1.&#xD;
&#xD;
          7. History of drug abuse (habitual taking of addictive or illegal drugs) within 1 year&#xD;
             before D1.&#xD;
&#xD;
          8. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or&#xD;
             soda) or grapefruit-containing products or alcoholic beverages within 48 hours before&#xD;
             D1 and until D7.&#xD;
&#xD;
          9. Any condition or disease detected during the medical interview / physical examination&#xD;
             that would render the subject unsuitable for the study, place the subject at undue&#xD;
             risk or interfere with the ability of the subject to complete the study in the opinion&#xD;
             of the Investigator or his designee.&#xD;
&#xD;
         10. Frequent headaches and/or migraine, recurrent nausea and / or vomiting.&#xD;
&#xD;
         11. Female subjects who are pregnant, or breastfeeding.&#xD;
&#xD;
         12. Positive screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines,&#xD;
             cannabinoids, cocaine, opiates, phencyclidine [PCP]) and breath alcohol test at&#xD;
             screening or D-2.&#xD;
&#xD;
         13. Positive serology for hepatitis B or hepatitis C or human immunodeficiency viruses&#xD;
             (HIV).&#xD;
&#xD;
         14. Positive SARS-CoV-2 RT-PCR.&#xD;
&#xD;
         15. Any condition detected at screening that may interfere with or bias the physical&#xD;
             examinations to be performed during the study.&#xD;
&#xD;
         16. Any prescribed or over-the-counter medication or herbal products taken within 1 week&#xD;
             prior to start of administration of IMP (D1) or within 6 times the elimination&#xD;
             half-life of the medication prior to start of IMP intake (whichever is longer), except&#xD;
             birth control as described in inclusion criterion number 5 in Section 6.1.&#xD;
             Vitamin/mineral supplements and occasional use of acetaminophen is allowed up until 24&#xD;
             hours before dosing.&#xD;
&#xD;
         17. Participation in a clinical trial or use of an investigational drug within 30 days&#xD;
             before randomization.&#xD;
&#xD;
         18. Any vaccination within 30 days before signature of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Needle, MD</last_name>
    <phone>8574000101</phone>
    <email>clinical@aveooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotrial Inc.</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dobrow, DO</last_name>
      <phone>973-388-2848</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

